SCHEMBL4728813

SCHEMBL4728813

O=C(O)CC(C1CCCC1)C1CCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
EPHX1 P07099 3/20 0.43
TP53 P04637 3/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MITF O75030 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NLRP1 Q9C000 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
CYP2D6 P10635 2/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38
MLNR O43193 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7581255 0.98 ALDH1A1 (0.59) ALDH1A1EPHX1TP53MEN1LMNA
SCHEMBL21245055 0.95 ALDH1A1 (0.50) ALDH1A1EPHX1TP53MEN1LMNA
SCHEMBL9180285 0.90 ALDH1A1 (0.43) ALDH1A1EPHX1TP53MEN1LMNA
Hydrochloric Acid SCHEMBL8845279 0.87 ALDH1A1 (0.42) ALDH1A1TP53MEN1LMNAKMT2A
SCHEMBL2398177 0.81 ALDH1A1 (0.52) ALDH1A1EPHX1TP53SLC22A6TDP1
SCHEMBL2398883 0.79 ALDH1A1 (0.55) ALDH1A1EPHX1TP53MEN1LMNA
SCHEMBL7397703 0.79 ALDH1A1 (0.46) ALDH1A1EPHX1TP53MEN1LMNA
SCHEMBL7497018 0.78 ALDH1A1 (0.53) ALDH1A1EPHX1TP53LMNASMN1; SMN2
SCHEMBL29051498 0.78 EPHX1 (0.48) ALDH1A1EPHX1TP53MEN1LMNA
SCHEMBL28480892 0.78 ALDH1A1 (0.77) ALDH1A1EPHX1TP53MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
WO-2008033466-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PRE. LTD. (SG) 2008-03-20 WO disclosed
US-6274118-B1 INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE NORDION INTERNATIONAL INC. (CA) 2001-08-14 US disclosed
WO-1995002424-A1 LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN NORDION INTERNATIONAL INC. (CA) 1995-01-26 WO disclosed
US-3970684-A Polyunsaturated prostaglandin derivatives SYNTEX (U.S.A.) INC. (US) 1976-07-20 US disclosed
US-3931297-A 10-Hydroxy PGC compounds SYNTEX (U.S.A.) INC. (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161324-A1 Compositions and methods for treatment of viral diseases HAVCR2, EIF2AK2, RNASE1 ALDH1A1 785/4885EPHX1 411/4885TP53 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.